TransCode Therapeutics Research and Development Expenses 2021-2024 | RNAZ

TransCode Therapeutics research and development expenses from 2021 to 2024. Research and development expenses can be defined as an expense arising from studies and product development processes.

TransCode Therapeutics Research and Development Expenses 2021-2024 | RNAZ

TransCode Therapeutics research and development expenses from 2021 to 2024. Research and development expenses can be defined as an expense arising from studies and product development processes.
Related Stocks
Company NameMarket
Cap
Zoetis (ZTS)$79.7B
Takeda Pharmaceutical (TAK)$42.4B
Sandoz Group AG (SDZNY)$19.3B
Merck (MKKGY)$18.8B
Astellas Pharma (ALPMY)$18.3B
United Therapeutics (UTHR)$16.4B
Summit Therapeutics (SMMT)$13.6B
Neurocrine Biosciences (NBIX)$12.7B
Shionogi (SGIOY)$11.8B
Catalent (CTLT)$10.8B
Jazz Pharmaceuticals (JAZZ)$7.6B
Madrigal Pharmaceuticals (MDGL)$7.2B
Orion OYJ (ORINY)$6.7B
Corcept Therapeutics (CORT)$5.9B
Ionis Pharmaceuticals (IONS)$5.4B
Crinetics Pharmaceuticals (CRNX)$5.3B
PTC Therapeutics (PTCT)$3.3B
Dyne Therapeutics (DYN)$3B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.6B
Catalyst Pharmaceuticals (CPRX)$2.5B
Soleno Therapeutics (SLNO)$2.4B
Arrowhead Pharmaceuticals (ARWR)$2.3B
Centessa Pharmaceuticals (CNTA)$2.1B
Evotec AG (EVO)$1.9B
NewAmsterdam Pharma (NAMS)$1.9B
Xencor (XNCR)$1.7B
Recursion Pharmaceuticals (RXRX)$1.6B
Harrow (HROW)$1.6B
BioCryst Pharmaceuticals (BCRX)$1.6B
Cassava Sciences (SAVA)$1.5B